JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Morgan Stanley Assumes Incyte (INCY) at Equalweight
September 5, 2019 3:37 AM EDTMorgan Stanley analyst Matthew Harrison assumes coverage on Incyte (NASDAQ: INCY) with a Equalweight rating and a price target of $87.00 (from $82.00).
For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.
Shares of Incyte closed at $77.62 yesterday.
... MoreOppenheimer Upgrades Incyte (INCY) to Outperform
September 5, 2019 3:28 AM EDTOppenheimer analyst Jay Olson upgraded Incyte (NASDAQ: INCY) from Perform to Outperform with a price target of $100.00.
The analyst comments "We upgrade INCY to Outperform based on attractive valuation for a company with increasing revenues, accelerating cash flows and a maturing... More
Incyte (INCY) Announces Data from its Oncology Portfolio to be Featured at ESMO
September 3, 2019 8:14 AM EDTIncyte (Nasdaq: INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1... More
